文献速递泌尿男性生殖肿瘤

氟-18前列腺特异性膜抗原-1007 PET/CT与多参数MRI在前列腺癌局部区域分期中的比较

Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项2期前瞻性配对验证队列研究纳入150例中高危前列腺癌患者,134例最终接受根治性前列腺切除术。以病理为金标准,18F-PSMA-1007 PET/CT在准确识别最终病理肿瘤分期、主结节、侧别及包膜外侵犯方面优于MRI,但精囊侵犯无显著差异。

要点

  • 18F-PSMA-1007 PET/CT识别最终病理肿瘤分期的准确率高于MRI(45% vs 28%,P=.003)。
  • PSMA PET识别主结节(94% vs 83%,P=.01)、侧别(64% vs 44%,P=.001)、包膜外侵犯(75% vs 63%,P=.01)均优于MRI。
  • 精囊侵犯识别PSMA PET与MRI无显著差异(91% vs 85%,P=.07)。

核心结论

  • 在这项2期前瞻性配对验证队列研究中,18F-PSMA-1007 PET/CT对前列腺癌局部区域分期的准确性优于MRI。
  • 这些发现支持将PSMA PET用于中危和高危肿瘤的术前流程。

研究设计与样本

  • Next Generation Trial为2期前瞻性配对验证队列研究,评估18F-PSMA-1007 PET/CT与MRI对前列腺癌局部区域分期的准确性,以组织病理学检查结果为参考标准。
  • 研究纳入同意接受根治性前列腺切除术的中危或高危前列腺癌男性,最终分析纳入接受根治性前列腺切除术的患者。
  • 患者于2022年3月至2023年6月招募,数据分析于2023年7月至2023年12月进行。
  • 所有参与者均在根治性前列腺切除术前行18F-PSMA-1007 PET/CT和MRI,两项检查间隔2周以内。
  • 150例合格前列腺癌男性中,134例最终接受根治性前列腺切除术(前列腺切除术时平均[SD]年龄62.0[5.7]岁)。

主要发现

  • PSMA PET在准确识别最终病理肿瘤分期方面优于MRI(61[45%] vs 38[28%];P=.003)。
  • PSMA PET在正确识别主结节方面优于MRI(126[94%] vs 112[83%];P=.01)。
  • PSMA PET在正确识别侧别方面优于MRI(86[64%] vs 60[44%];P=.001)。
  • PSMA PET在正确识别包膜外侵犯方面优于MRI(100[75%] vs 84[63%];P=.01)。
  • 精囊侵犯识别方面PSMA PET与MRI无显著差异(122[91%] vs 115[85%];P=.07)。

关键数值与推荐

  • 主要结局为每种影像检查正确识别前列腺癌肿瘤分期。
  • 次要结局为正确识别主结节、侧别、包膜外侵犯和精囊侵犯。

临床怎么用

  • 作者认为这些发现支持将PSMA PET用于中危和高危肿瘤的术前流程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prostate-specific membrane antigen (PSMA) demonstrates overexpression in prostate cancer and correlates with tumor aggressiveness. PSMA positron emission tomography (PET) is superior to conventional imaging for the metastatic staging of prostate cancer per current research but studies of second-generation PSMA PET radioligands for locoregional staging are limited. OBJECTIVE: To determine the accuracy of fluorine-18 PSMA-1007 PET/computed tomography (18F-PSMA-1007 PET/CT) compared to multiparametric magnetic resonance imaging (MRI) in the primary locoregional staging of intermediate-risk and high-risk prostate cancers. DESIGN, SETTING, AND PARTICIPANTS: The Next Generation Trial was a phase 2 prospective validating paired cohort study assessing the accuracy of 18F-PSMA-1007 PET/CT and MRI for locoregional staging of prostate cancer, with results of histopathologic examination as the reference standard comparator. Radiologists, nuclear medicine physicians, and pathologists were blinded to preoperative clinical, pathology, and imaging data. Patients underwent all imaging studies and radical prostatectomies at 2 tertiary care hospitals in Alberta, Canada. Eligible participants included men with intermediate-risk or high-risk prostate cancer who consented to radical prostatectomy. Participants who underwent radical prostatectomy were included in the final analysis. Patients were recruited between March 2022 and June 2023, and data analysis occurred between July 2023 and December 2023. EXPOSURES: All participants underwent both 18F-PSMA-1007 PET/CT and MRI within 2 weeks of one another and before radical prostatectomy. MAIN OUTCOMES AND MEASURES: The primary outcome was the correct identification of the prostate cancer tumor stage by each imaging test. The secondary outcomes were correct identification of the dominant nodule, laterality, extracapsular extension, and seminal vesical invasion. RESULTS: Of 150 eligible men with prostate cancer, 134 patients ultimately underwent radical prostatectomy (mean [SD] age at prostatectomy, 62.0 [5.7] years). PSMA PET was superior to MRI for the accurate identification of the final pathological tumor stage (61 [45%] vs 38 [28%]; P = .003). PSMA PET was also superior to MRI for the correct identification of the dominant nodule (126 [94%] vs 112 [83%]; P = .01), laterality (86 [64%] vs 60 [44%]; P = .001), and extracapsular extension (100 [75%] vs 84 [63%]; P = .01), but not for seminal vesicle invasion (122 [91%] vs 115 [85%]; P = .07). CONCLUSIONS AND RELEVANCE: In this phase 2 prospective validating paired cohort study, 18F-PSMA-1007 PET/CT was superior to MRI for the locoregional staging of prostate cancer. These findings support PSMA PET in the preoperative workflow of intermediate-risk and high-risk tumors.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mookerji N, Pfanner T, Hui A, et al. Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer. JAMA Oncol. 2024. PMID: 38949926. doi:10.1001/jamaoncol.2024.3196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。